Header Logo

Connection

CHRISTIE BALLANTYNE to Coronary Artery Disease

Back to Details
This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about Coronary Artery Disease.
CHRISTIE BALLANTYNE
Connection Strength
7.328
Coronary Artery Disease
  1. Role of Bempedoic Acid in Clinical Practice. Cardiovasc Drugs Ther. 2021 08; 35(4):853-864.
    View in: PubMed
    Score: 0.424
  2. How Do We Incorporate Polygenic Risk Scores in Cardiovascular Disease Risk Assessment and Management? Curr Atheroscler Rep. 2021 04 01; 23(6):28.
    View in: PubMed
    Score: 0.424
  3. Single nucleotide polymorphisms in cholesteryl ester transfer protein gene and recurrent coronary heart disease or mortality in patients with established atherosclerosis. Am J Cardiol. 2013 Nov 01; 112(9):1287-92.
    View in: PubMed
    Score: 0.249
  4. Chromosome 9p21 single nucleotide polymorphisms are not associated with recurrent myocardial infarction in patients with established coronary artery disease. Circ J. 2012; 76(4):950-6.
    View in: PubMed
    Score: 0.225
  5. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol. 2010 Apr 13; 55(15):1600-7.
    View in: PubMed
    Score: 0.198
  6. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation. 2008 May 13; 117(19):2458-66.
    View in: PubMed
    Score: 0.172
  7. Matrix metalloproteinase-1 and tissue inhibitors do not predict incident coronary artery disease in the atherosclerosis risk in communities (ARIC) study. Tex Heart Inst J. 2008; 35(4):388-94.
    View in: PubMed
    Score: 0.169
  8. Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib/ezetimibe on coronary plaque characteristics. Am Heart J. 2025 Dec; 290:325-338.
    View in: PubMed
    Score: 0.143
  9. Inadequate Intensification of LDL-cholesterol lowering therapy after coronary revascularization: Insights from the GOULD registry. Int J Cardiol. 2025 Feb 15; 421:132916.
    View in: PubMed
    Score: 0.137
  10. Should We Recommend Vitamin K2 Supplement to Prevent Coronary Artery Calcification for Patients Receiving Statins and/or Warfarin? Cardiovasc Drugs Ther. 2025 Dec; 39(6):1585-1588.
    View in: PubMed
    Score: 0.137
  11. Predictors of incident stroke among individuals without coronary artery calcification: A pooled cohort analysis from the Multi-Ethnic Study of Atherosclerosis, Jackson Heart Study, and Framingham Heart Study. Vasc Med. 2024 12; 29(6):632-639.
    View in: PubMed
    Score: 0.134
  12. Lipoprotein(a) and Progression of Coronary Artery Calcification in a Pooled?U.S. Cohort. JACC Cardiovasc Imaging. 2024 Oct; 17(10):1265-1267.
    View in: PubMed
    Score: 0.134
  13. Familial Hypercholesterolemia Variant and Cardiovascular Risk in Individuals With Elevated Cholesterol. JAMA Cardiol. 2024 Mar 01; 9(3):263-271.
    View in: PubMed
    Score: 0.130
  14. Statin Use and Risk of Diabetes by Subclinical Atherosclerosis Burden (from a Multi-Ethnic Study of Atherosclerosis Report). Am J Cardiol. 2022 12 01; 184:7-13.
    View in: PubMed
    Score: 0.117
  15. Clonal hematopoiesis of indeterminate potential, DNA methylation, and risk for coronary artery disease. Nat Commun. 2022 09 12; 13(1):5350.
    View in: PubMed
    Score: 0.117
  16. Association of polygenic risk scores with incident atherosclerotic cardiovascular disease events among individuals with coronary artery calcium score of zero: The multi-ethnic study of atherosclerosis. Prog Cardiovasc Dis. 2022 Sep-Oct; 74:19-27.
    View in: PubMed
    Score: 0.116
  17. Lipoprotein(a) and Subclinical Vascular and Valvular Calcification on Cardiac Computed Tomography: The Atherosclerosis Risk in Communities Study. J Am Heart Assoc. 2022 06 07; 11(11):e024870.
    View in: PubMed
    Score: 0.115
  18. Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group. J Clin Lipidol. 2021 Sep-Oct; 15(5):629-648.
    View in: PubMed
    Score: 0.109
  19. 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021 08 31; 78(9):960-993.
    View in: PubMed
    Score: 0.108
  20. Sex-Related Disparities in Cardiovascular Health Care Among Patients With Premature Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2021 07 01; 6(7):782-790.
    View in: PubMed
    Score: 0.108
  21. Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy. J Am Coll Cardiol. 2000 Nov 01; 36(5):1572-8.
    View in: PubMed
    Score: 0.103
  22. Zero Coronary Artery Calcium Score: Desirable, but Enough? Circulation. 2020 09 08; 142(10):917-919.
    View in: PubMed
    Score: 0.102
  23. Autoimmune Rheumatic Diseases and Premature Atherosclerotic Cardiovascular Disease: An Analysis From the VITAL Registry. Am J Med. 2020 12; 133(12):1424-1432.e1.
    View in: PubMed
    Score: 0.100
  24. Associations Between High-Density Lipoprotein Particles and Ischemic Events by Vascular Domain, Sex, and Ethnicity: A Pooled Cohort Analysis. Circulation. 2020 08 18; 142(7):657-669.
    View in: PubMed
    Score: 0.100
  25. Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study. J Am Coll Cardiol. 2000 Jan; 35(1):89-95.
    View in: PubMed
    Score: 0.097
  26. Reducing atherothrombotic events in high-risk patients: recent data on therapy with statins and fatty acids. Curr Atheroscler Rep. 1999 Jul; 1(1):6-8.
    View in: PubMed
    Score: 0.094
  27. Association Between Lipid Testing and Statin Adherence in the Veterans Affairs Health System. Am J Med. 2019 09; 132(9):e693-e700.
    View in: PubMed
    Score: 0.093
  28. Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. Circ Genom Precis Med. 2019 04; 12(4):e002471.
    View in: PubMed
    Score: 0.092
  29. Effect of Evolocumab on Coronary?Plaque Composition. J Am Coll Cardiol. 2018 10 23; 72(17):2012-2021.
    View in: PubMed
    Score: 0.089
  30. Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial: A Randomized Clinical Trial. JAMA Cardiol. 2018 09 01; 3(9):806-814.
    View in: PubMed
    Score: 0.089
  31. Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: Insights from the Department of Veterans Affairs. Vasc Med. 2018 06; 23(3):232-240.
    View in: PubMed
    Score: 0.086
  32. Usefulness of Lipoprotein-Associated Phospholipase A2 Activity and C-Reactive Protein in Identifying High-Risk Smokers for Atherosclerotic Cardiovascular Disease (from the Atherosclerosis Risk in Communities Study). Am J Cardiol. 2018 05 01; 121(9):1056-1064.
    View in: PubMed
    Score: 0.085
  33. Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation and Ischemic Stroke: The ARIC (Atherosclerosis Risk in Communities) Study. J Am Heart Assoc. 2017 Dec 15; 6(12).
    View in: PubMed
    Score: 0.084
  34. 2017 Focused Update of the 2016?ACC?Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in?the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017 Oct 03; 70(14):1785-1822.
    View in: PubMed
    Score: 0.083
  35. Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN. Atherosclerosis. 2017 Aug; 263:137-144.
    View in: PubMed
    Score: 0.081
  36. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016 12 13; 316(22):2373-2384.
    View in: PubMed
    Score: 0.079
  37. Diastolic Blood Pressure, Subclinical Myocardial Damage, and Cardiac Events: Implications for Blood Pressure Control. J Am Coll Cardiol. 2016 10 18; 68(16):1713-1722.
    View in: PubMed
    Score: 0.077
  38. Accuracy of the Atherosclerotic Cardiovascular Risk Equation in?a?Large?Contemporary, Multiethnic?Population. J Am Coll Cardiol. 2016 05 10; 67(18):2118-2130.
    View in: PubMed
    Score: 0.075
  39. Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). Am Heart J. 2016 Jun; 176:83-92.
    View in: PubMed
    Score: 0.074
  40. Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial. Am J Cardiovasc Drugs. 2016 Feb; 16(1):55-65.
    View in: PubMed
    Score: 0.074
  41. Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: insights from Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin. Arterioscler Thromb Vasc Biol. 2014 Nov; 34(11):2465-72.
    View in: PubMed
    Score: 0.067
  42. Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damage. Circulation. 2014 Oct 14; 130(16):1374-82.
    View in: PubMed
    Score: 0.067
  43. Association between lipoprotein associated phospholipase A2 mass and subclinical coronary and carotid atherosclerosis in Retired National Football League players. Atherosclerosis. 2014 Oct; 236(2):251-6.
    View in: PubMed
    Score: 0.067
  44. Validated context-dependent associations of coronary heart disease risk with genotype variation in the chromosome 9p21 region: the Atherosclerosis Risk in Communities study. Hum Genet. 2014 Sep; 133(9):1105-16.
    View in: PubMed
    Score: 0.066
  45. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J. 2014 Dec 07; 35(46):3277-86.
    View in: PubMed
    Score: 0.066
  46. Neck circumference is not associated with subclinical atherosclerosis in retired National Football League players. Clin Cardiol. 2014 Jul; 37(7):402-7.
    View in: PubMed
    Score: 0.065
  47. Decrease the incentives to order lipid panels--reply. JAMA Intern Med. 2014 Mar; 174(3):473-4.
    View in: PubMed
    Score: 0.065
  48. Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. Eur Heart J Cardiovasc Imaging. 2014 Apr; 15(4):380-8.
    View in: PubMed
    Score: 0.064
  49. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy. Circulation. 2013 Nov 26; 128(22):2395-403.
    View in: PubMed
    Score: 0.063
  50. Correlates of repeat lipid testing in patients with coronary heart disease. JAMA Intern Med. 2013 Aug 12; 173(15):1439-44.
    View in: PubMed
    Score: 0.062
  51. Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy. Eur Heart J. 2013 Nov; 34(41):3182-90.
    View in: PubMed
    Score: 0.062
  52. Factors underlying regression of coronary atheroma with potent statin therapy. Eur Heart J. 2013 Jun; 34(24):1818-25.
    View in: PubMed
    Score: 0.061
  53. Coronary artery bypass graft surgery remains the standard of care for patients with diabetes. Semin Thorac Cardiovasc Surg. 2013; 25(2):97-9.
    View in: PubMed
    Score: 0.060
  54. Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial. Cardiovasc Drugs Ther. 2012 Aug; 26(4):349-58.
    View in: PubMed
    Score: 0.058
  55. ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies. Cardiovasc Drugs Ther. 2012 Apr; 26(2):181-7.
    View in: PubMed
    Score: 0.057
  56. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011 Dec 01; 365(22):2078-87.
    View in: PubMed
    Score: 0.055
  57. Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated with carotid intima media thickness and plaque. Nat Genet. 2011 Sep 11; 43(10):940-7.
    View in: PubMed
    Score: 0.055
  58. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet. 2011 Oct 29; 378(9802):1547-59.
    View in: PubMed
    Score: 0.055
  59. Isolated coronary artery bypass grafting in obese individuals: a propensity matched analysis of outcomes. Circ J. 2011; 75(6):1378-85.
    View in: PubMed
    Score: 0.053
  60. Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial. J Am Coll Cardiol. 2011 Mar 01; 57(9):1111-9.
    View in: PubMed
    Score: 0.052
  61. Candidate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosis. BMC Med Genet. 2009 Oct 30; 10:111.
    View in: PubMed
    Score: 0.048
  62. Differences in responses of platelets to fluid shear stress in patients with peripheral artery disease (PAD) and coronary artery disease (CAD). Platelets. 2009 May; 20(3):199-205.
    View in: PubMed
    Score: 0.046
  63. Using the whole cohort in the analysis of case-cohort data. Am J Epidemiol. 2009 Jun 01; 169(11):1398-405.
    View in: PubMed
    Score: 0.046
  64. The 9p21 susceptibility locus for coronary artery disease and the severity of coronary atherosclerosis. BMC Cardiovasc Disord. 2009 Jan 27; 9:3.
    View in: PubMed
    Score: 0.046
  65. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2008 Apr 29; 51(17):1632-41.
    View in: PubMed
    Score: 0.043
  66. Interaction effects of high-density lipoprotein metabolism gene variation and alcohol consumption on coronary heart disease risk: the atherosclerosis risk in communities study. J Stud Alcohol Drugs. 2007 Jul; 68(4):485-92.
    View in: PubMed
    Score: 0.041
  67. Specific P-selectin and P-selectin glycoprotein ligand-1 genotypes/haplotypes are associated with risk of incident CHD and ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis. 2007 Nov; 195(1):e76-82.
    View in: PubMed
    Score: 0.040
  68. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006 Apr 05; 295(13):1556-65.
    View in: PubMed
    Score: 0.037
  69. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med. 2006 Mar; 259(3):247-58.
    View in: PubMed
    Score: 0.037
  70. Human plasma proteomic profile of clonal hematopoiesis. Nat Commun. 2025 Nov 27; 16(1):11688.
    View in: PubMed
    Score: 0.037
  71. P-selectin Thr715Pro polymorphism predicts P-selectin levels but not risk of incident coronary heart disease or ischemic stroke in a cohort of 14595 participants: the Atherosclerosis Risk in Communities Study. Atherosclerosis. 2006 May; 186(1):74-9.
    View in: PubMed
    Score: 0.036
  72. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005 Aug 15; 96(4):556-63.
    View in: PubMed
    Score: 0.036
  73. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol. 2005 May 17; 45(10):1611-9.
    View in: PubMed
    Score: 0.035
  74. Effects of PPARalpha, gamma and delta haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study. Pharmacogenetics. 2004 Jan; 14(1):61-71.
    View in: PubMed
    Score: 0.032
  75. Glutathione-S-transferase genotypes, smoking, and their association with markers of inflammation, hemostasis, and endothelial function: the atherosclerosis risk in communities (ARIC) study. Atherosclerosis. 2003 Dec; 171(2):265-72.
    View in: PubMed
    Score: 0.032
  76. Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin. J Mol Med (Berl). 2002 11; 80(11):737-44.
    View in: PubMed
    Score: 0.029
  77. Novel polymorphisms in promoter region of atp binding cassette transporter gene and plasma lipids, severity, progression, and regression of coronary atherosclerosis and response to therapy. Circ Res. 2001 May 11; 88(9):969-73.
    View in: PubMed
    Score: 0.027
  78. A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin. Atherosclerosis. 2001 Feb 15; 154(3):633-40.
    View in: PubMed
    Score: 0.026
  79. A variant of p22(phox), involved in generation of reactive oxygen species in the vessel wall, is associated with progression of coronary atherosclerosis. Circ Res. 2000 Mar 03; 86(4):391-5.
    View in: PubMed
    Score: 0.025
  80. A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy. J Mol Med (Berl). 2000; 78(10):562-8.
    View in: PubMed
    Score: 0.024
  81. Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events. Lipoproteins and Coronary Atherosclerosis Study. Atherosclerosis. 1999 Jun; 144(2):435-42.
    View in: PubMed
    Score: 0.023
  82. Exome-wide association study of plasma lipids in >300,000 individuals. Nat Genet. 2017 Dec; 49(12):1758-1766.
    View in: PubMed
    Score: 0.021
  83. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol. 1997 Aug 01; 80(3):278-86.
    View in: PubMed
    Score: 0.021
  84. The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia. Control Clin Trials. 1996 Dec; 17(6):550-83.
    View in: PubMed
    Score: 0.020
  85. Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk. Lipids Health Dis. 2015 Sep 04; 14:103.
    View in: PubMed
    Score: 0.018
  86. Obesity, subclinical myocardial injury, and incident heart failure. JACC Heart Fail. 2014 Dec; 2(6):600-7.
    View in: PubMed
    Score: 0.017
  87. High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN. Diabetes Care. 2014 Nov; 37(11):3114-20.
    View in: PubMed
    Score: 0.017
  88. Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies. Eur Heart J. 2012 Jan; 33(2):238-51.
    View in: PubMed
    Score: 0.014
  89. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010 Aug 05; 466(7307):707-13.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.